Anemia

This month in review highlights vitamin D supplementation in anemia, the prevalence of iron deficiency in US adults, and the efficacy of rpFVIII in treating acquired hemophilia A.

A large study shows no women were anemic in the first trimester of pregnancy, but more than 80% of the women were iron deficient by the third trimester.

Rates of absolute and functional iron deficiency were high among adults in the US, even in those without anemia, heart failure, or chronic kidney disease.

New research establishes a strong causal link between elevated 25(OH)D levels and a reduced risk of anemia.

Ferric carboxymaltose achieved superior outcomes to an oral iron tablet for the treatment of anemia in pregnant women.

Pre-pregnancy overweight and obesity were not linked to an increased prevalence of iron deficiency or anemia during pregnancy in a US population.

A real-world post-authorization safety study identified no new safety signals compared with the phase 2/3 clinical trial of rpFVIII for acquired hemophilia A.

An investigation into basic and instrumental activities of daily living in older female patients found greater reliance in those with anemia.

A systematic review found a higher prevalence of acute pancreatitis in individuals with the HbSS genotype, though a meta-analysis could not be performed.

Vadadustat once-daily demonstrated noninferiority to darbepoetin alfa for the change in mean hemoglobin from baseline, while 3-times-weekly did not.

This August 2024 month in review highlights new recommendations from the USPSTF, FDA approval of a treatment for chronic GVHD, and Phase 2 data for severe HDFN.

Moderate to severe anemia was linked to an increase in cardiac arrest or stroke compared with normal hemoglobin levels in critically ill COVID-19 patients.

Across a statewide cohort, more than half of patients were unable to achieve iron deficiency resolution within 3 years.

A new recommendation statement cites a lack of current evidence to assess the benefits of iron deficiency screening and supplementation in pregnant individuals.

A randomized clinical trial found significant improvements in key blood parameters for anemia after grape syrup intervention compared with placebo.

Nipocalimab led to a substantially higher percentage of live births at 32 weeks’ gestation or later without intrauterine transfusions than the historical benchmark.

Ferritin cutoffs of 30 and 45 ng/mL notably increase the rate of iron deficiency diagnoses.

Delayed anemia treatment with ESAs was not correlated with worse renal events but elevated the risk of cardiovascular events and all-cause mortality.

Anemia is common in high-risk PCI and is independently associated with major adverse cardiovascular events and major bleeding risk.

An obstetrician-gynecologist addresses the unmet clinical needs in the treatment of patients with iron deficiency anemia, particularly for pregnant patients.

Our July 2024 hematology month in review examines the latest updates to the hematological pipeline and key study data informing clinical practice.

The expert panel discusses why intravenous iron replacement used to be associated with unacceptable toxicity and has become much more tolerable over time.

Ashley Benson, MD, discusses the most recent International Federation of Gynecology and Obstetrics (FIGO) statement on iron deficiency and anemia in women and girls.

Hematologists, a gastroenterologist, and an obstetrician-gynecologist discuss the common causes of iron deficiency seen in clinical practice.

The panel provides a broad overview of the treatment of patients with iron deficiency, highlighting diagnostic practices.

A panel of experts on iron deficiency anemia introduce themselves and provide an overview of the physiology of iron metabolism and iron deficiency.

Interim analysis of the Phase 2 study shows an overall response rate of 40% in patients aged 2 years to younger than 18 years with chronic GVHD.

Most patients administered IV iron after acute bacterial infection did not experience negative clinical outcomes.

Online survey data underlines notable discrepancies across various aspects of ID screening and supplementation in clinical practice for patients with HF.

Iron deficiency and anemia rates were typically higher in less economically developed regions and rural areas in China.